The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.
Biohaven stock slides on withdrawal of European marketing application
HOT NEWS
Rethinking evidence generation for ultra-rare diseases
Scientific analyzes results of cerebrospinal fluid in patients with transverse myelitis. FDA’s RDEP in Context…
تُظهر الدراسة أن وجبة الإفطار الغنية بالجوز من الممكن أن تساعد في تعزيز قوة دماغك
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire Provides Press Release Distribution in Arabic
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…